Search Results - "Gooderham, M."

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial by Bissonnette, R., Papp, K.A., Poulin, Y., Gooderham, M., Raman, M., Mallbris, L., Wang, C., Purohit, V., Mamolo, C., Papacharalambous, J., Ports, W.C.

“…Summary Background Despite unmet need, 15 years have passed since a topical therapy with a new mechanism of action for atopic dermatitis (AD) has been…”
Get full text

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2) by Paul, C., Cather, J., Gooderham, M., Poulin, Y., Mrowietz, U., Ferrandiz, C., Crowley, J., Hu, C., Stevens, R.M., Shah, K., Day, R.M., Girolomoni, G., Gottlieb, A.B.

“…Summary Background Apremilast, an oral phosphodiesterase 4 inhibitor, regulates immune responses associated with psoriasis. Objectives ESTEEM 2 evaluated the…”
Get full text

Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders by Gooderham, M.J., Papp, K.A., Lynde, C.W.

“…Insights into the pathophysiology of autoimmune inflammatory diseases including psoriasis have advanced considerably in recent years, and in parallel, so too…”
Get full text

Real‐world experience with risankizumab in patients with plaque psoriasis: a retrospective study by Mehta, M., O’Toole, A., Gooderham, M.

Get full text

Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials by Bieber, T., Thyssen, J.P., Reich, K., Simpson, E.L., Katoh, N., Torrelo, A., De Bruin‐Weller, M., Thaci, D., Bissonnette, R., Gooderham, M., Weisman, J., Nunes, F., Brinker, D., Issa, M., Holzwarth, K., Gamalo, M., Riedl, E., Janes, J.

“…Background Janus kinase (JAK) inhibition is a new mode of action in atopic dermatitis (AD); clarity about drug class safety considerations in the context of AD…”
Get full text

Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) by Menter, A., Papp, K.A., Gooderham, M., Pariser, D.M., Augustin, M., Kerdel, F.A., Fakharzadeh, S., Goyal, K., Calabro, S., Langholff, W., Chavers, S., Naessens, D., Sermon, J., Krueger, G.G.

“…Background Drug survival is a marker for treatment sustainability in chronic diseases such as psoriasis. Objective The aim of these analyses was to assess…”
Get full text

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE) by Reich, K., Gooderham, M., Green, L., Bewley, A., Zhang, Z., Khanskaya, I., Day, R.M., Goncalves, J., Shah, K., Piguet, V., Soung, J.

“…Background Apremilast, an oral, small‐molecule phosphodiesterase 4 inhibitor, has demonstrated efficacy in patients with moderate‐to‐severe psoriasis…”
Get full text

Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis by Papp, K., Bachelez, H., Costanzo, A., Foley, P., Gooderham, M., Kaur, P., Philipp, S., Spelman, L., Zhang, N., Strober, B.

“…Summary Background ABP 501, a U.S.A. Food and Drug Administration‐ and European Medicines Agency‐approved biosimilar, is highly similar to adalimumab in…”
Get full text

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial by Blauvelt, A., Leonardi, C., Elewski, B., Crowley, J.J., Guenther, L.C., Gooderham, M., Langley, R.G., Vender, R., Pinter, A., Griffiths, C.E.M., Tada, Y., Elmaraghy, H., Lima, R.G., Gallo, G., Renda, L., Burge, R., Park, S.Y., Zhu, B., Papp, K.

“…Summary Background Significantly more patients with moderate‐to‐severe plaque psoriasis treated with the interleukin (IL)‐17A inhibitor ixekizumab vs. the…”
Get full text

Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real‐world setting by Papp, K.A., Gooderham, M.J., Albrecht, L.E., Raymond, M.‐A., Lynde, C.W.

Get full text

Efficacy and safety of continuous every‐2‐week dosing of ixekizumab over 52 weeks in patients with moderate‐to‐severe plaque psoriasis in a randomized phase III trial (IXORA‐P) by Langley, R.G., Papp, K., Gooderham, M., Zhang, L., Mallinckrodt, C., Agada, N., Blauvelt, A., Foley, P., Polzer, P.

“…Summary Background Ixekizumab is an interleukin‐17A antagonist approved for treatment of moderate‐to‐severe plaque psoriasis with a recommended 160‐mg starting…”
Get full text

Expert consensus on the systemic treatment of atopic dermatitis in special populations by Adam, D. N., Gooderham, M. J., Beecker, J. R., Hong, C. H., Jack, C. S., Jain, V., Lansang, P., Lynde, C. W., Papp, K. A., Prajapati, V. H., Turchin, I., Yeung, J.

“…With the increasing number of options for the treatment of moderate‐to‐severe atopic dermatitis, clinicians need guidance on a practical approach to selecting…”
Get full text

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials by Blauvelt, A., Sofen, H., Papp, K., Gooderham, M., Tyring, S., Zhao, Y., Lowry, S., Mendelsohn, A., Parno, J., Reich, K.

“…Background Two randomized controlled trials (reSURFACE 1 and 2) have demonstrated the effectiveness of tildrakizumab, a high‐affinity, humanized, IgG1κ,…”
Get full text

The effectiveness of intralesional Candida antigen immunotherapy as a treatment for anogenital warts: a retrospective chart review by Logel, M., Pammett, R., Chiang, C., O'Toole, A., Gooderham, M.

Get full text

Safety of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials by Blauvelt, A., Reich, K., Papp, K.A., Kimball, A.B., Gooderham, M., Tyring, S.K., Sinclair, R., Thaçi, D., Li, Q., Cichanowitz, N., Green, S., La Rosa, C.

“…Summary Background Short‐term interleukin‐23p19 inhibition by tildrakizumab improves plaque psoriasis and appears to be well tolerated. Objectives Safety and…”
Get full text

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study by Reich, K., Gooderham, M., Bewley, A., Green, L., Soung, J., Petric, R., Marcsisin, J., Cirulli, J., Chen, R., Piguet, V.

“…Background Apremilast, an oral phosphodiesterase‐4 inhibitor, has demonstrated efficacy in patients with moderate to severe psoriasis. Objective To evaluate…”
Get full text

An indirect comparison of long‐term efficacy of every‐2‐week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12 by Papp, K., Maari, C., Cauthen, A., Gooderham, M., Spelman, L., Yamanaka, K., Polzer, P., Zhang, L., Osuntokun, O., Augustin, M.

“…Summary Background Long‐term efficacy and safety of ixekizumab [160 mg at week 0, then 80 mg every 2 weeks (Q2W) for 12 weeks, followed by every 4 weeks (Q4W)…”
Get full text

Phase I randomized study of KHK4083, an anti‐OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis by Papp, K.A., Gooderham, M.J., Girard, G., Raman, M., Strout, V.

“…Background OX40 (CD134) is expressed in lesional but not healthy skin of patients with psoriasis. KHK4083 is a fully human monoclonal antibody against OX40…”
Get full text

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies by Kimball, A.B., Papp, K.A., Reich, K., Gooderham, M., Li, Q., Cichanowitz, N., La Rosa, C., Blauvelt, A.

“…Summary Background Chronic psoriasis may require medication adjustments over time. Objectives To evaluate the efficacy/safety of tildrakizumab in subgroups…”
Get full text

Real‐world effectiveness of adalimumab in patients with moderate‐to‐severe hidradenitis suppurativa: the 1‐year SOLACE study by Gulliver, W., Alavi, A., Wiseman, M.C., Gooderham, M.J., Rao, J., Alam, M.S., Papp, K.A., Desjardins, O., Jean, C.

“…Background Long‐term, real‐word data are needed to help manage patients with hidradenitis suppurativa (HS) through this recurrent, painful and debilitating…”
Get full text